Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Equity Ratio: 2019-2025

Historic Equity Ratio for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to 0.88.

  • Avidity Biosciences' Equity Ratio fell 3.54% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 3.54%. This contributed to the annual value of 0.91 for FY2024, which is 14.37% up from last year.
  • As of Q3 2025, Avidity Biosciences' Equity Ratio stood at 0.88, which was up 1.44% from 0.87 recorded in Q2 2025.
  • Avidity Biosciences' 5-year Equity Ratio high stood at 0.93 for Q3 2021, and its period low was 0.80 during Q4 2023.
  • Moreover, its 3-year median value for Equity Ratio was 0.91 (2024), whereas its average is 0.89.
  • Its Equity Ratio has fluctuated over the past 5 years, first dropped by 11.96% in 2023, then increased by 14.37% in 2024.
  • Over the past 5 years, Avidity Biosciences' Equity Ratio (Quarterly) stood at 0.89 in 2021, then climbed by 1.44% to 0.90 in 2022, then fell by 11.96% to 0.80 in 2023, then climbed by 14.37% to 0.91 in 2024, then decreased by 3.54% to 0.88 in 2025.
  • Its Equity Ratio stands at 0.88 for Q3 2025, versus 0.87 for Q2 2025 and 0.91 for Q1 2025.